BioNano Genomics Inc vs Google Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Google Inc trades at $342.32 (market cap $4.20T). The key difference: Google Inc is far larger — about 307467.1× BioNano Genomics Inc's market cap, and Google Inc pays a 0.26% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | GOOG | |
|---|---|---|
Market Cap | $13.66M | $4.20T |
Sector | Health | Technology |
52-Week High | $4.92 | $399.06 |
52-Week Low | $1.06 | $200.19 |
Enterprise Value | $16.26M | $4.09T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.26% |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Alphabet (GOOG) trades at $342.71, down 3.69% on the day, with technical indicators showing a bearish trend near support at $340. The company reported strong fundamentals with Q2 2026 EPS of $9.11 beating expectations, revenue growth to $402.84B in 2025, and robust profitability margins. Recent news highlights AI advancements, including Gemini reaching 1 billion users, but also regulatory scrutiny from French media.
The stock presents a compelling long-term opportunity with a consensus price target of $431.67, representing 26% upside, supported by 87% analyst buy ratings. Risks include high capital expenditure forecasts up to $205B for 2026, competitive AI pressures, and ongoing regulatory challenges. Investors should weigh strong cash flow generation against aggressive investment cycles.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →